PHARM INTEGRATION PHARMACOLOGY EXAM MODULES 4-6 | 2026/2027
Pharmacy Integrated Pharmacology Exam Modules 4-6 with Complete Questions & Verified
Answers | Latest Version
Overview
This 2026/2027 updated resource contains the latest Pharmacy Integration
Pharmacology Exam for Modules 4-6 with the exact 95 questions and verified answers,
following current pharmacy curriculum standards, integrated therapeutic applications, clinical
decision-making frameworks, and evidence-based pharmacotherapy across complex disease
states.
Key Features
● ✓ Actual integrated pharmacology exam format with the official 95 questions
● ✓ Comprehensive coverage of modules 4-6 therapeutic areas and complex
patient management
● ✓ Updated 2026/2027 treatment guidelines and FDA-approved therapies
● ✓ Clinical case integration with multi-morbidity management
● ✓ Therapeutic drug monitoring and personalized medicine applications
Core Content Areas (95 Total Questions)
● Module 4: Cardiovascular & Renal Therapeutics (35 Qs)
● Module 5: Neurological & Psychiatric Pharmacotherapy (30 Qs)
● Module 6: Oncology, Immunology & Special Populations (30 Qs)
Answer Format
Correct answers are marked in bold green and include:
● Integrated therapeutic decision-making rationales for complex cases
● Drug interaction management in multi-therapy regimens
● Pharmacogenomic application examples and dosing adjustments
● Adverse effect mitigation strategies for high-risk medications
● Patient-specific factors considerations (age, comorbidities, organ function)
● Monitoring parameter optimization for therapeutic outcomes
Updates for 2026/2027
🔹 Reflects 2026-2027 pharmacy curriculum integration standards
🔹 Updated ACC/AHA cardiovascular guidelines with new drug classes
●
●
, ● 🔹 Enhanced neuropsychiatric treatment protocols including novel
🔹 Revised oncology immunotherapy management and toxicity monitoring
mechanisms
🔹 New biologics and biosimilars integration in treatment algorithms
●
🔹 Updated renal and hepatic dosing adjustments for special populations
●
🔹 Enhanced digital health tool integration in medication management
●
🔹 Revised antimicrobial stewardship protocols for resistant infections
●
●
Module 4: Cardiovascular & Renal Therapeutics (Questions 1–35)
1. A 68-year-old male with HFrEF (LVEF 30%), hypertension, and CKD stage 3b is
currently on lisinopril 10 mg daily, carvedilol 12.5 mg BID, and furosemide 40 mg
BID. His BP is 132/82 mmHg, HR 68 bpm, and K+ 4.1 mEq/L. Which of the following
is the most appropriate next step per 2026 ACC/AHA guidelines?
A) Add amlodipine
B) Add spironolactone
C) Add dapagliflozin
D) Increase lisinopril to 20 mg daily
Rationale: SGLT2 inhibitors like dapagliflozin are now Class I recommendations in
HFrEF for reducing hospitalization and mortality, regardless of diabetes status.
2. Which antihypertensive is contraindicated in bilateral renal artery stenosis?
A) Amlodipine
B) Lisinopril
C) Hydrochlorothiazide
D) Metoprolol
Rationale: ACE inhibitors can cause acute kidney injury in bilateral renal artery
stenosis due to reduced glomerular filtration pressure.
3. A patient with atrial fibrillation and a CHA₂DS₂-VASc score of 4 is started on
apixaban. Which statement is correct regarding dosing in renal impairment?
A) No dose adjustment needed in CrCl >15 mL/min
B) Reduce to 2.5 mg BID if CrCl 15–29 mL/min AND age ≥80 or weight
≤60 kg
C) Avoid entirely if CrCl <30 mL/min
D) Always reduce to 2.5 mg BID in CKD stage 4
Rationale: Apixaban dose reduction criteria include CrCl 15–29 mL/min PLUS
either age ≥80 or body weight ≤60 kg or serum creatinine ≥1.5 mg/dL.
4. Which drug requires therapeutic drug monitoring due to a narrow therapeutic index
and risk of torsades de pointes?
A) Metoprolol
B) Digoxin
C) Losartan
D) Atorvastatin
, Rationale: Digoxin has a narrow therapeutic index (0.5–0.9 ng/mL); levels >2.0
ng/mL increase risk of toxicity including arrhythmias.
5. A 55-year-old female with type 2 diabetes, albuminuria (UACR 450 mg/g), and eGFR
58 mL/min is on metformin and empagliflozin. Which agent provides the greatest
renal and cardiovascular protection?
A) Amlodipine
B) Finerenone
C) Hydrochlorothiazide
D) Isosorbide mononitrate
Rationale: Finerenone, a nonsteroidal MRA, reduces CKD progression and CV
events in diabetic kidney disease per FIDELIO-DKD and FIGARO-DKD trials.
6. Which beta-blocker is preferred in acute decompensated heart failure with reduced
ejection fraction?
A) Propranolol
B) Atenolol
C) None should be initiated during acute decompensation
D) Nebivolol
Rationale: Beta-blockers are held or reduced during acute decompensation;
initiation occurs only in stable, compensated HF.
7. A patient on warfarin develops an INR of 7.5 with no bleeding. What is the most
appropriate action?
A) Administer vitamin K 10 mg IV
B) Hold warfarin and give oral vitamin K 2.5–5 mg
C) Give FFP immediately
D) Continue warfarin at half dose
Rationale: For INR 5–9 without bleeding, hold warfarin and give low-dose oral
vitamin K (2.5–5 mg); reassess in 24h.
8. Which statin has the highest risk of myopathy when co-administered with
clarithromycin?
A) Pravastatin
B) Rosuvastatin
C) Simvastatin
D) Fluvastatin
Rationale: Simvastatin is metabolized by CYP3A4; clarithromycin inhibits CYP3A4,
increasing simvastatin levels and myopathy risk.
9. A 72-year-old male with resistant hypertension (on HCTZ, lisinopril, amlodipine) has
a serum aldosterone of 28 ng/dL and plasma renin activity of 0.5 ng/mL/h. What is
the best next step?
A) Add spironolactone 12.5 mg daily
B) Confirm primary hyperaldosteronism and consider spironolactone or
eplerenone
C) Switch to chlorthalidone
D) Add doxazosin
Rationale: Aldosterone:renin ratio >30 suggests primary hyperaldosteronism;
spironolactone is first-line if confirmed.
Pharmacy Integrated Pharmacology Exam Modules 4-6 with Complete Questions & Verified
Answers | Latest Version
Overview
This 2026/2027 updated resource contains the latest Pharmacy Integration
Pharmacology Exam for Modules 4-6 with the exact 95 questions and verified answers,
following current pharmacy curriculum standards, integrated therapeutic applications, clinical
decision-making frameworks, and evidence-based pharmacotherapy across complex disease
states.
Key Features
● ✓ Actual integrated pharmacology exam format with the official 95 questions
● ✓ Comprehensive coverage of modules 4-6 therapeutic areas and complex
patient management
● ✓ Updated 2026/2027 treatment guidelines and FDA-approved therapies
● ✓ Clinical case integration with multi-morbidity management
● ✓ Therapeutic drug monitoring and personalized medicine applications
Core Content Areas (95 Total Questions)
● Module 4: Cardiovascular & Renal Therapeutics (35 Qs)
● Module 5: Neurological & Psychiatric Pharmacotherapy (30 Qs)
● Module 6: Oncology, Immunology & Special Populations (30 Qs)
Answer Format
Correct answers are marked in bold green and include:
● Integrated therapeutic decision-making rationales for complex cases
● Drug interaction management in multi-therapy regimens
● Pharmacogenomic application examples and dosing adjustments
● Adverse effect mitigation strategies for high-risk medications
● Patient-specific factors considerations (age, comorbidities, organ function)
● Monitoring parameter optimization for therapeutic outcomes
Updates for 2026/2027
🔹 Reflects 2026-2027 pharmacy curriculum integration standards
🔹 Updated ACC/AHA cardiovascular guidelines with new drug classes
●
●
, ● 🔹 Enhanced neuropsychiatric treatment protocols including novel
🔹 Revised oncology immunotherapy management and toxicity monitoring
mechanisms
🔹 New biologics and biosimilars integration in treatment algorithms
●
🔹 Updated renal and hepatic dosing adjustments for special populations
●
🔹 Enhanced digital health tool integration in medication management
●
🔹 Revised antimicrobial stewardship protocols for resistant infections
●
●
Module 4: Cardiovascular & Renal Therapeutics (Questions 1–35)
1. A 68-year-old male with HFrEF (LVEF 30%), hypertension, and CKD stage 3b is
currently on lisinopril 10 mg daily, carvedilol 12.5 mg BID, and furosemide 40 mg
BID. His BP is 132/82 mmHg, HR 68 bpm, and K+ 4.1 mEq/L. Which of the following
is the most appropriate next step per 2026 ACC/AHA guidelines?
A) Add amlodipine
B) Add spironolactone
C) Add dapagliflozin
D) Increase lisinopril to 20 mg daily
Rationale: SGLT2 inhibitors like dapagliflozin are now Class I recommendations in
HFrEF for reducing hospitalization and mortality, regardless of diabetes status.
2. Which antihypertensive is contraindicated in bilateral renal artery stenosis?
A) Amlodipine
B) Lisinopril
C) Hydrochlorothiazide
D) Metoprolol
Rationale: ACE inhibitors can cause acute kidney injury in bilateral renal artery
stenosis due to reduced glomerular filtration pressure.
3. A patient with atrial fibrillation and a CHA₂DS₂-VASc score of 4 is started on
apixaban. Which statement is correct regarding dosing in renal impairment?
A) No dose adjustment needed in CrCl >15 mL/min
B) Reduce to 2.5 mg BID if CrCl 15–29 mL/min AND age ≥80 or weight
≤60 kg
C) Avoid entirely if CrCl <30 mL/min
D) Always reduce to 2.5 mg BID in CKD stage 4
Rationale: Apixaban dose reduction criteria include CrCl 15–29 mL/min PLUS
either age ≥80 or body weight ≤60 kg or serum creatinine ≥1.5 mg/dL.
4. Which drug requires therapeutic drug monitoring due to a narrow therapeutic index
and risk of torsades de pointes?
A) Metoprolol
B) Digoxin
C) Losartan
D) Atorvastatin
, Rationale: Digoxin has a narrow therapeutic index (0.5–0.9 ng/mL); levels >2.0
ng/mL increase risk of toxicity including arrhythmias.
5. A 55-year-old female with type 2 diabetes, albuminuria (UACR 450 mg/g), and eGFR
58 mL/min is on metformin and empagliflozin. Which agent provides the greatest
renal and cardiovascular protection?
A) Amlodipine
B) Finerenone
C) Hydrochlorothiazide
D) Isosorbide mononitrate
Rationale: Finerenone, a nonsteroidal MRA, reduces CKD progression and CV
events in diabetic kidney disease per FIDELIO-DKD and FIGARO-DKD trials.
6. Which beta-blocker is preferred in acute decompensated heart failure with reduced
ejection fraction?
A) Propranolol
B) Atenolol
C) None should be initiated during acute decompensation
D) Nebivolol
Rationale: Beta-blockers are held or reduced during acute decompensation;
initiation occurs only in stable, compensated HF.
7. A patient on warfarin develops an INR of 7.5 with no bleeding. What is the most
appropriate action?
A) Administer vitamin K 10 mg IV
B) Hold warfarin and give oral vitamin K 2.5–5 mg
C) Give FFP immediately
D) Continue warfarin at half dose
Rationale: For INR 5–9 without bleeding, hold warfarin and give low-dose oral
vitamin K (2.5–5 mg); reassess in 24h.
8. Which statin has the highest risk of myopathy when co-administered with
clarithromycin?
A) Pravastatin
B) Rosuvastatin
C) Simvastatin
D) Fluvastatin
Rationale: Simvastatin is metabolized by CYP3A4; clarithromycin inhibits CYP3A4,
increasing simvastatin levels and myopathy risk.
9. A 72-year-old male with resistant hypertension (on HCTZ, lisinopril, amlodipine) has
a serum aldosterone of 28 ng/dL and plasma renin activity of 0.5 ng/mL/h. What is
the best next step?
A) Add spironolactone 12.5 mg daily
B) Confirm primary hyperaldosteronism and consider spironolactone or
eplerenone
C) Switch to chlorthalidone
D) Add doxazosin
Rationale: Aldosterone:renin ratio >30 suggests primary hyperaldosteronism;
spironolactone is first-line if confirmed.
